| Overview |
| bs-0746R-Cy5 |
| HHV8 ORF50 Polyclonal Antibody, Cy5 Conjugated |
| WB |
| Virus |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from N-terminus of HHV8 ORF50 strain GK18 |
| 2-100/691 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4961526 |
| F5HCV3 |
| HHV 8; Human Herpes Virus 8; Human herpesvirus 8; HHV8 ORF50; Kaposi's sarcoma associated herpes virus; Kaposi's sarcoma associated herpesvirus; KSHV; replication and transcription activator; RTA |
| HHV8 has been found to be associated with three different diseases observed in AIDS patients; kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma. |
| Application Dilution |
| WB |
1:500-1000 |
Powered by Bioz